D. E. Shaw & Co. Inc. Has $3.15 Million Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

D. E. Shaw & Co. Inc. lessened its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 42.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,476 shares of the company's stock after selling 55,990 shares during the period. D. E. Shaw & Co. Inc. owned 0.12% of Vera Therapeutics worth $3,150,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in VERA. Avoro Capital Advisors LLC grew its position in shares of Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock valued at $237,247,000 after purchasing an additional 1,300,410 shares during the last quarter. Lord Abbett & CO. LLC grew its holdings in Vera Therapeutics by 170.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company's stock valued at $48,788,000 after buying an additional 727,656 shares during the last quarter. Federated Hermes Inc. increased its position in Vera Therapeutics by 162.2% in the 4th quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock worth $45,926,000 after buying an additional 671,881 shares during the period. Voya Investment Management LLC increased its holdings in shares of Vera Therapeutics by 572.2% during the 4th quarter. Voya Investment Management LLC now owns 695,091 shares of the company's stock worth $29,395,000 after purchasing an additional 591,682 shares during the period. Finally, First Light Asset Management LLC lifted its position in shares of Vera Therapeutics by 78.8% in the 4th quarter. First Light Asset Management LLC now owns 1,261,246 shares of the company's stock worth $53,338,000 after acquiring an additional 556,012 shares during the period. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Trading Up 0.1%

NASDAQ:VERA traded up $0.01 on Friday, reaching $19.64. The company's stock had a trading volume of 1,064,297 shares, compared to its average volume of 782,385. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The firm has a market cap of $1.25 billion, a PE ratio of -7.52 and a beta of 1.28. The business's 50-day moving average price is $22.74 and its two-hundred day moving average price is $33.10. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the previous year, the business earned ($0.56) earnings per share. Equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 target price on the stock. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price for the company. Guggenheim upped their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Cantor Fitzgerald dropped their price objective on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Finally, Wedbush reduced their target price on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $63.33.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.